Biote Corporation (BTMD) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biote Reports Third Quarter 2024 Financial Results

Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software...

Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of...

Biote Reports Second Quarter 2024 Financial Results

Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial...

Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of...

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of...

Biote Reports First Quarter 2024 Financial Results

Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms...

Biote Announces Definitive Settlement with Founder

Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading...

Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of...

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing...

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of...

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares

Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share biote Corp. (NASDAQ: BTMD) (“Biote” or...